Trial · NCT03347292
Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
NCT03347292, Phase 1, Completed, Bayer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC. Trials, record NCT03347292. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03347292
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
- NCT number
- NCT03347292
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 58 participants, actual
- Lead sponsor
- Bayer
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Regorafenib(Stivarga, BAY73-4506), Pembrolizumab
- First posted
- 2017-11-20
- Last updated
- 2023-07-25
- Other registries' IDs
- eudract:2017-003202-40
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of treatment-emergent adverse event(TEAEs) | Up to 30 days after last dose of study drug | The incidence of treatment-emergent adverse events and treatment-emergent drug-related adverse events summarized in frequency tables using worst CTCAE v4.03 grade. |
| Primary | Severity of TEAEs | Up to 30 days after last dose of study drug | |
| Primary | Dose Limiting Toxicities(DLTs) | Up to 42 days after first treatment administration | |
| Secondary | Maximum Tolerated Dose (MTD) | After approximately 18 months | The MTD is defined as the highest dose that can be given so that toxicity probability is below the target toxicity PT =35%. |
| Secondary | Progression-free survival (PFS) | After approximately 36 months | |
| Secondary | Time to progression (TTP) | After approximately 36 months | |
| Secondary | Overall survival (OS) | After approximately 36 months | |
| Secondary | Overall response rate (ORR) | After approximately 36 months | |
| Secondary | Disease control rate (DCR) | After approximately 36 months | |
| Secondary | Duration of response (DOR) | After approximately 36 months |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03347292
GET https://conductscience.org/api/trials/v1/NCT03347292/registered